Close Menu
PNN DigitalPNN Digital
    Facebook X (Twitter) Instagram
    PNN DigitalPNN Digital
    • Business
    • National
    • Entertainment
    • Lifestyle
    • Education
    • Press Release
    • Submit Your PR
    PNN DigitalPNN Digital
    Home - Business - Dr. Harshvardhan busts the common cancer myths
    Business

    Dr. Harshvardhan busts the common cancer myths

    PNN Online DeskBy PNN Online DeskDecember 20, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Dr. Harshvardhan busts the common cancer myths

    New Delhi (India), December 20: Numerous idioms and urban myths regarding cancer are untrue in terms of science. However, because they contradict popular opinion, individuals do not accept their authenticity.

    However, these false beliefs greatly contribute to people’s anxiety and sadness and are a significant source of therapy and diagnosis delays. After receiving a cancer diagnosis, everyone’s first thought is of death, specifically how long they have left to live. 

    Cancer is fatal, but the reality is that when compared to the previous 50 years, the rates of cancer treatment that is successful have actually increased by approximately a factor of two during the past fifty years. Survival rates after five years have climbed to about 75%. The treatment is now relatively simple and effective because of new equipment, enhanced treatment, and diagnosis techniques.

    According to Dr Harshvardhan Atreya, Cancer Specialist, Medanta Hospital  Lucknow, Successful cancer treatments rely on a variety of variables. such as the patient’s age, physical condition, cancer stage, co-morbidities like high blood pressure or diabetes, or the accessibility of the right kind of care. Because of this, different people with the same stage or kind of cancer have varying degrees of success.”

    The whole spectrum of medical oncology subspecialties has been exposed to Dr Harsh Vardhan Atreya, who has substantial expertise in treating both common and uncommon cancers.

    He is knowledgeable about all forms of chemotherapy, intense regimens, immunotherapy, and hormonal therapy, as well as handling oncological crises and patient care.

     Dr Harshvardhan has a keen interest in tumours of the breast, lungs, and gastrointestinal tract, including lymphoma, leukaemia, and myeloma.

    Dr Harshvardhan says that “Cancer care is a fast developing discipline that necessitates a multidisciplinary approach due to ongoing therapy discoveries and advancements. This strategy covers a wide range of topics, including health promotion, screening and prevention, diagnosis, treatment, rehabilitation, and palliative care.”

    According to Dr Harshvardhan, the field of cancer management has expanded to include new techniques and ideas, such as immune therapy and genetic counselling. 

    He supports compassionate, thorough, individualised treatment that preserves the quality of life. 

    Talking about gynecologic cancer, Dr Harshvardhan mentions that

     “Treatment options for gynecologic malignancies are diverse. It will depend on cancer’s nature and degree of dissemination. Surgery, chemotherapy, and radiation therapy are all options for treatment. Women with gynecologic cancer frequently have a variety of treatment options. Each treatment’s benefits, dangers, and side effects can be reviewed with your doctor. A side effect is a manifestation of a treatment or drug in your body.”

    Dr. Harshvardhan also encourages his patients to collaborate with the financial navigators to allay any financial worries since he respects the social and financial struggles cancer patients go through.
     
     For more information visit: https://drharshatreya.com/

    If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    PNN Online Desk
    • Website

    Related Posts

    Ducon’s Early Carbon Capture Strategy Receives Policy Validation as India Accelerates CCUS Deployment

    February 4, 2026

    Best Crypto to Invest In: South Korea Expands AI Oversight While ETH and SOL Crash, but DeepSnitch AI Is the High Upside Project You Should Bet On

    February 4, 2026

    Best Crypto to Buy Now in February 2026: DeepSnitch AI Guns Toward 1000x Launch as Hyperliquid Rallies 17 Percent and Tron Holds Ground

    February 4, 2026
    Add A Comment

    Comments are closed.

    Recent Posts
    • What Age Limits Apply in Travel Insurance for Senior Citizens
    • BGMI Players Can Unlock New Outfit via Latest Redeem Code for February 4th
    • Ducon’s Early Carbon Capture Strategy Receives Policy Validation as India Accelerates CCUS Deployment
    • Best Crypto to Invest In: South Korea Expands AI Oversight While ETH and SOL Crash, but DeepSnitch AI Is the High Upside Project You Should Bet On
    • Best Crypto to Buy Now in February 2026: DeepSnitch AI Guns Toward 1000x Launch as Hyperliquid Rallies 17 Percent and Tron Holds Ground

    What Age Limits Apply in Travel Insurance for Senior Citizens

    February 4, 2026

    BGMI Players Can Unlock New Outfit via Latest Redeem Code for February 4th

    February 4, 2026

    Ducon’s Early Carbon Capture Strategy Receives Policy Validation as India Accelerates CCUS Deployment

    February 4, 2026

    Best Crypto to Invest In: South Korea Expands AI Oversight While ETH and SOL Crash, but DeepSnitch AI Is the High Upside Project You Should Bet On

    February 4, 2026

    Best Crypto to Buy Now in February 2026: DeepSnitch AI Guns Toward 1000x Launch as Hyperliquid Rallies 17 Percent and Tron Holds Ground

    February 4, 2026

    What Crypto To Buy Now: ETFs Bounce USD 562M, Whales Rotate Into DeepSnitch AI Before USD 5 Listing

    February 4, 2026
    PNN Digital
    2026 © pnn.digital

    Type above and press Enter to search. Press Esc to cancel.